Search

Objective: To detect the expression of nicotinamide nucleotide adenosine transferase 2(Nicotinamide nucleotide adenosine transferase 2) and p53 in colon cancer and analyze the relationship between the three. Methods: S-ABC immunohistochemical method(<4 = 4, divided into negative into positive) detection of colorectal cancer(48 cases) and adjacent normal tissues(40 cases) the expression of NMNAT2, p53, and the analysis of colon cancer age and gender, pathological type, tumor morphology, differentiation, and Jin Runshen TNM staging, lymph node metastasis and other clinical parameters of the relationship and the relationship between the two.Results: NMNAT2 and p53 expression in colon cancer tissue cytoplasm and nucleus, with Buffy or brown, expression is low or absent in normal tissues. The positive rate of NMNAT2 and p53 expression in colon cancer was 83.33% and 70.83%, respectively. The positive expression rate in 7.50% normal tissues was 7.50% and 0%, respectively, and the difference was statistically significant(P<0.05). The positive rate of p53 and NMNAT2, there was no significant difference in different age, gender, pathological type, tumor size and differentiation degree in patients(P>0.05);(T3-T4) period was 96.51%, 84.62% higher than the 68.18% period(T1-T2), 54.55%(P<0.05);(III-IV) period was 95% 85%, higher than(I-II) period of 78.57%, 57.14%(P<0.05); lymph node metastasis was 100%, 84.21% higher than those without lymph node metastasis, 72.41%, 62.07%(P<0.05). The NMNAT2 and p53 expression in colorectal cancer tissue was positively correlated(rs=0.809, P<0.05). Conclusion: NMNAT2 and p53 are related to the development of colon cancer, and there is a positive correlation between the two. The joint detection can be considered to assist the diagnosis and treatment of colon cancer and the evaluation of the disease. [ABSTRACT FROM AUTHOR]

Objective To screen and analyze small molecule therapeutic compounds dissociated with colorectal cancer metastasis. Methods First statistical comparison was made for the expression profile data of early metastasizing colorectal cancer tissues wíth the data of normal colorectum tissues to screen the differentially expressed genes. Then the matching patterns between differenfially expressed genes and the small molecules were used to screen small molecule therapeutic tanespimycin compounds associated with early colorectal cancer metastasis. Last, the enrichment status of the small molecule therapeutic compounds target protein were analyzed to screen the colorectal cancellated target protein. We combined the colorectal cancer expresiion profile and the bond strength between small molecule compounds and the target protein to screen the most relevant target protein and build a regulatory network. Results By the small molecule compounds enrichment analysis, tanespimycin had the highest score, the target protein of tanespimycin had the highest score of enrichment in colorectal cancer. It indicated that tanespimycin was closely related to colorectal cancer. By synthesizing the expression profile and the molecular bonding strength, we found that the colorectal cancer-related target proteins named CHEK1, AURKA, GSTP1 and NQO1 might be the key proteins of tanespimycin therapy that inhibhed the metastasis of colorectal cancer. The regulatory network was built by the four target proteins participating in the biological process of drug metaboiism. That further explained the relationship between the four proteins and tanespimycin. Conclusion Tanespimycin may be the small molecule therapeutic compound that can inhibs eariy metastasis of colorectal cancer by interacting wth CHEK1, AURKA, GSTP1 and NQO1 to regulate the signaling network. [ABSTRACT FROM AUTHOR]